PMN310 Phase 1b AD Trial Shows No ARIA-E

ProMIS Neurosciences reported positive interim safety and biomarker data for PMN310 in an Alzheimer's trial, with no ARIA-E observed. Evidence of early biomarker changes suggests potential efficacy as a tolerated alternative to standard amyloid therapies.